These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32141313)

  • 1. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
    T Low J; B Peters K
    CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
    Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.
    Du S; Fu DB; A Bota D; Kong XT
    CNS Oncol; 2024 Jun; 13(1):2345579. PubMed ID: 38722227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
    Wang L; Li X; He YZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction of novel agents in the treatment of primary CNS lymphoma.
    Grommes C; Nayak L; Tun HW; Batchelor TT
    Neuro Oncol; 2019 Feb; 21(3):306-313. PubMed ID: 30423172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
    Schaff L; Nayak L; Grommes C
    Leuk Lymphoma; 2024 Jul; 65(7):882-894. PubMed ID: 38597202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.
    Houillier C; Chabrot CM; Moles-Moreau MP; Willems L; Ahle G; Waultier-Rascalou A; Fornecker LM; Hoang-Xuan K; Soussain C
    Neurology; 2021 Sep; 97(13):628-631. PubMed ID: 34580183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
    Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F
    Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
    Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L
    J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
    Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
    J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy.
    Steinbeck JA; Stuplich M; Blasius E; Pels H; Glas M; Schlegel U; Herrlinger U
    J Clin Neurosci; 2011 Nov; 18(11):1554-5. PubMed ID: 21868233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
    Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
    Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
    [No Abstract]   [Full Text] [Related]  

  • 15. Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
    Graf SA; Cassaday RD; Morris K; Voutsinas JM; Wu QV; Behnia S; Lynch RC; Krakow E; Rasmussen H; Chauncey TR; Kanan S; Soma L; Smith SD; Gopal AK
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):176-181. PubMed ID: 33358575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.
    Mendez JS; Grommes C
    Am Soc Clin Oncol Educ Book; 2018 May; 38():604-615. PubMed ID: 30231317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
    Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
    Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
    Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
    Okahashi N; Uchihara M; Hoshino E
    Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.